Back to journals
Academic Journal

ACS Pharmacology and Translational Science

26 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 26 psychedelic papers Blossom tracks from ACS Pharmacology and Translational Science line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does ACS Pharmacology and Translational Science carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

12papers published in 2021

+20% vs 2020

22 published by 2021

Browse papers→

Don't read as the journal's total output: only the 26 of 26 tracked psychedelic papers from ACS Pharmacology and Translational Science with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does ACS Pharmacology and Translational Science publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
13
Addiction & Substance Use
8
Anxiety Disorders
6
Equity and Ethics
5
Medicinal Chemistry & Drug Development
4
PTSD
4
Suicidality
3
Palliative & End-of-Life Distress
3
Other
14

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does ACS Pharmacology and Translational Science cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
8
LSD
4
Ibogaine
1
Mescaline
1
2C-X
1
Ketamine
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

ACS Pharmacology and Translational Science has 26 tracked papers indexed in Blossom (2020–2025) from 114 authors, most often covering Psilocybin, LSD and Ibogaine, across Depressive Disorders, Substance Use Disorders (SUD) and Anxiety Disorders.

Published Papers

Open Accessindividual

Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice

Chronic administration of sub‑hallucinogenic (microdose) LSD in mice produced no ventricular thickening or other ECG-detected cardiotoxic changes, whereas serotonin (positive control) caused significant ventricular thickening. In vitro assays showed similar 5‑HT2B affinity across mouse and human receptors and that low‑dose LSD yields only transient 5‑HT2B activation compared with the cardiotoxin d‑fenfluramine, together providing no evidence of cardiovascular risk from prolonged low‑dose LSD in this mouse model.

Published
Journal
ACS Pharmacology and Translational Science
Authors
Effinger, D. P., Schalk, S. S., King, J. L., Wallingford, J. R., O'connell, C. K., Calderon, J. R., Kopecky, B. J., Mccorvy, J. D., Thompson, S. M.
Open Accessindividual

5-Methoxy-2-aminoindane Reverses Diet-Induced Obesity and Improves Metabolic Parameters in Mice: A Potential New Class of Antiobesity Therapeutics

This mouse model study examines the metabolic efficacy of the psychoactive aminoindane derivative MEAI on diet-induced obesity (DIO). MEAI treatment significantly reduced overweight and adiposity, improved glycemic control, decreased hepatic lipid accumulation, increased energy expenditure and fat utilization, and normalized voluntary locomotion without overstimulatory effects, suggesting its potential as a novel therapeutic approach for obesity and related metabolic disorders.

Published
Journal
ACS Pharmacology and Translational Science
Authors
Baraghithy, S., Gammal, A., Permyakova, A., Hamad, S., Kocvarová, R., Calles, Y., Tam, J.
Open Accessindividual

Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression

This in vitro study examines functional selectivity between two 5-HT2A receptor agonists, (R)-2,5-dimethoxy-4-iodoamphetamine [(R)-DOI] and (R)-2,5-dimethoxy-4-trifluoromethylamphetamine [(R)-DOTFM], in the context of their impact on inflammation and airway hyperresponsiveness (AHR) in a murine asthma model. Despite similar in vitro activity and behavioral potency, (R)-DOTFM does not prevent inflammation or elevated AHR, in contrast to (R)-DOI, suggesting distinct anti-inflammatory mechanisms associated with certain psychedelics.

Published
Journal
ACS Pharmacology and Translational Science
Authors
Flanagan, T. W., Foster, T. P., Galbato, T. E., Lum, Y., Louie, B., Song, G., Halberstadt, A. L., Billac, G. B., Nichols, C. D.
Open Accessindividual

The Psychedelic N,N-Dipropyltryptamine Prevents Seizures in a Mouse Model of Fragile X Syndrome via a Mechanism that Appears Independent of Serotonin and Sigma1 Receptors

This mouse study investigated the effects of N,N-dipropyltryptamine (DPT), a psychedelic tryptamine, on audiogenic seizures in a mouse model of fragile X syndrome (genetic cause of autism). DPT was found to prevent seizures at a 10 mg/kg dose completely but not at lower doses (3 or 5.6 mg/kg). Despite being a serotonin receptor agonist, the antiepileptic effects of DPT were not mediated through specific serotonin receptor subtypes (5-HT2A, 5-HT1B, or 5-HT1A), nor through sigma1 receptors.

Published
Journal
ACS Pharmacology and Translational Science
Authors
Tyagi, R., Saraf, T. S., Canal, C. E.
Open Accessmeta

Working with Weirdness: A Response to “Moving Past Mysticism in Psychedelic Science”

This commentary (2021) argues against the removal of the mystical experience concept from psychedelic science, advocating instead for a research approach that embraces the variability and subjective depth of these experiences. The authors contend that acknowledging these transformative states is essential for understanding the therapeutic potential of psychedelics rather than relying solely on neurobiological explanations.

Published
Journal
ACS Pharmacology and Translational Science
Authors
Breeksema, J. J., van Elk, M.
Open Accessindividual

Reconciling Mystical Experiences with Naturalistic Psychedelic Science: Reply to Sanders and Zijlmans

This commentary (2021) offers a rebuttal to the opinion piece on Moving Past Mysticism in Psychedelic Science by Sanders and Zijlmans and argues against the notion of demystifying psychedelic experiences or dismissing mystical experiences from the scope of empirical inquiry. Given that all experiences are ineffable by the nature of their subjectivity, it is argued that the epistemic gap between subjective and objective viewpoints of consciousness is a question of philosophy and that it is not the role of science to decide whether metaphysical insights related to mystical experiences are compatible with their particular worldview.

Published
Journal
ACS Pharmacology and Translational Science
Authors
Jylkkä, J.

Quick Facts

Papers Indexed
26
h-Index
43
Open Access
No
Publisher
American Chemical Society
Country
United States
Website
Visit